Form 6-K TEVA PHARMACEUTICAL INDU For: Mar 31
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Teva Pharmaceutical Industries Ltd. |
||||
(Translation of registrants name into English) | ||||
Israel | ||||
(Jurisdiction of incorporation or organization) | ||||
5 Basel Street, P.O. Box 3190 Petach Tikva 4951033 Israel |
||||
(Address of principal executive office) |
||||
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: [x] Form 20-F [ ] Form 40-F | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): [ ] | ||||
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): [ ] | ||||
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: [ ] Yes [x] No | ||||
If "Yes" is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): n/a |
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. |
Teva Pharmaceutical Industries Ltd. | ||
Date: 03/31/2015 | By: |
Eyal Desheh |
Name: | Eyal Desheh | |
Title: | Group EVP & CFO | |
Exhibit No. | Description | |
|
|
|
99.1 | TEVA EXPANDS HYPERTENSION LINE WITH LAUNCH OF GENERIC EXFORGE® TABLETS IN THE UNITED STATES | |
TEVA EXPANDS HYPERTENSION LINE WITH LAUNCH OF GENERIC EXFORGE® TABLETS IN THE
UNITED STATES
Jerusalem, March 31, 2015 Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announces the launch of the generic equivalent to Exforge® (amlodipine and valsartan) Tablets in four different strengths, in the United States.
Exforge® (amlodipine and valsartan) Tablets are used in the treatment of high blood pressure (hypertension), a chronic condition often without symptoms that is linked to serious health issues such as heart disease and stroke, if not detected early and treated appropriately. With the launch of Amlodipine and Valsartan Tablets, Teva can offer those prescribed Exforge® a generic alternative to help manage their high blood pressure.
Exforge® (amlodipine and valsartan) Tablets had annual sales of approximately $409 million in the United States, according to IMS data as of January 2015.
About Amlodipine and Valsartan Tablets
Amlodipine and Valsartan Tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. Amlodipine and Valsartan Tablets may be used in patients whose blood pressure is not adequately controlled on either monotherapy. Amlodipine and Valsartan Tablets may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals.
Important Safety Information
Fetal Toxicity: When pregnancy is detected, discontinue amlodipine and valsartan tablets as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.
Do not use Amlodipine and Valsartan Tablets in patients with known hypersensitivity to any component. Do not co-administer aliskiren with Amlodipine and Valsartan Tablets in patients with diabetes.
Excessive hypotension was seen in 0.4% of patients with uncomplicated hypertension treated with Amlodipine and Valsartan Tablets in placebo-controlled studies. Volume depletion should be corrected prior to administration of Amlodipine and Valsartan Tablets. Treatment with Amlodipine and Valsartan Tablets should start under close medical supervision.
Worsening angina and acute myocardial infarction can develop after starting or increasing the dose of amlodipine, particularly in patients with severe obstructive coronary artery disease.
Changes in renal function including acute renal failure can be caused by drugs that inhibit the renin-angiotensin system and by diuretics. Patients whose renal function may depend in part on the activity of the renin-angiotensin system may be at particular risk of developing acute renal failure. Drugs that inhibit the renin-angiotensin system can cause hyperkalemia.
The adverse reactions that occurred in placebo-controlled clinical trials in at least 2% of patients treated with Amlodipine and Valsartan Tablets but at a higher incidence in amlodipine/valsartan patients than placebo included peripheral edema, nasopharyngitis, upper respiratory tract infection, and dizziness.
Please see accompanying Full Prescribing Information, including Boxed Warning.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical
company that delivers high-quality, patient-centric healthcare solutions to millions of patients
every day. Headquartered in Israel, Teva is the worlds largest generic medicines producer,
leveraging its portfolio of more than 1,000 molecules to produce a wide range of generic products
in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in
innovative treatments for disorders of the central nervous system, including pain, as well as a
strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities
in its global research and development division to create new ways of addressing unmet patient
needs by combining drug development capabilities with devices, services and technologies. Tevas
net revenues in 2014 amounted to $20.3 billion. For more information,
visit www.tevapharm.com
Safe Harbor Statement under the U.S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which are based on managements current beliefs
and expectations and involve a number of known and unknown risks and uncertainties that could cause
our future results, performance or achievements to differ significantly from the results,
performance or achievements expressed or implied by such forward-looking statements. Important
factors that could cause or contribute to such differences include risks relating to: our ability
to develop and commercialize additional pharmaceutical products; competition for our innovative
products, especially Copaxone® (including competition from orally-administered alternatives, as
well as from potential purported generic equivalents) and our ability to migrate users to our 40
mg/mL version; the possibility of material fines, penalties and other sanctions and other adverse
consequences arising out of our ongoing FCPA investigations and related matters; our ability to
achieve expected results from the research and development efforts invested in our pipeline of
specialty and other products; our ability to reduce operating expenses to the extent and during the
timeframe intended by our cost reduction program; our ability to identify and successfully bid for
suitable acquisition targets or licensing opportunities, or to consummate and integrate
acquisitions; the extent to which any manufacturing or quality control problems damage our
reputation for quality production and require costly remediation; increased government scrutiny in
both the U.S. and Europe of our patent settlement agreements; our exposure to currency fluctuations
and restrictions as well as credit risks; the effectiveness of our patents, confidentiality
agreements and other measures to protect the intellectual property rights of our specialty
medicines; the effects of reforms in healthcare regulation and pharmaceutical pricing,
reimbursement and coverage; governmental investigations into sales and marketing practices,
particularly for our specialty pharmaceutical products; adverse effects of political or economic
instability, major hostilities or acts of terrorism on our significant worldwide operations;
interruptions in our supply chain or problems with internal or third-party information technology
systems that adversely affect our complex manufacturing processes; significant disruptions of our
information technology systems or breaches of our data security; competition for our generic
products, both from other pharmaceutical companies and as a result of increased governmental
pricing pressures; competition for our specialty pharmaceutical businesses from companies with
greater resources and capabilities; the impact of continuing consolidation of our distributors and
customers; decreased opportunities to obtain U.S. market exclusivity for significant new generic
products; potential liability in the U.S., Europe and other markets for sales of generic products
prior to a final resolution of outstanding patent litigation; our potential exposure to product
liability claims that are not covered by insurance; any failure to recruit or retain key personnel,
or to attract additional executive and managerial talent; any failures to comply with complex
Medicare and Medicaid reporting and payment obligations; significant impairment charges relating to
intangible assets, goodwill and property, plant and equipment; the effects of increased leverage
and our resulting reliance on access to the capital markets; potentially significant increases in
tax liabilities; the effect on our overall effective tax rate of the termination or expiration of
governmental programs or tax benefits, or of a change in our business; variations in patent laws
that may adversely affect our ability to manufacture our products in the most efficient manner;
environmental risks; and other factors that are discussed in our Annual Report on Form 20-F for the
year ended December 31, 2014 and in our other filings with the U.S. Securities and Exchange
Commission. Forward-looking statements speak only as of the date on which they are made and we
assume no obligation to update or revise any forward-looking statement, whether as a result of new
information, future events or otherwise.
###
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
- ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Compass Minerals International, Inc. Investors to Inquire About Securities Class Action Investigation – CMP
- Mirasol Resources Closes First Tranche of Private Placement
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!